Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Quest Diagnostics Inc (DGX), Laboratory Corp. of America Holdings (LH): Why This Health Care Stock Is a Good Value

Page 1 of 2

End market conditions aren’t great for diagnostics information services company Quest Diagnostics Inc (NYSE:DGX), but that doesn’t stop it from being a good value. If you’re looking for a value play whose prospects are tied to its internal execution rather than the economy, Quest Diagnostics Inc (NYSE:DGX) could fit the bill. It’s worth a look for investors looking to balance their portfolio.

Quest Diagnostics Inc (NYSE:DGX)

Quest’s quest gets harder
It’s been a tricky year for companies servicing hospitals, and Quest Diagnostics Inc (NYSE:DGX) has suffered as physician office visits and hospital admissions have come in lower in the first half of 2013 than in 2012. Indeed, during its conference call, the company outlined that growth “is not as strong as what we thought we were going to see this year.” Moreover, after being “encouraged by April numbers,” conditions appeared to get worse. Subsequently, Quest Diagnostics Inc (NYSE:DGX) cut its full-year revenue guidance to a decline of 1% to 2%, from its previous forecast of flat to 1% growth. In addition, the high end of earnings per share guidance was cut by $0.05, leaving the new range at $4.35 to $4.50.

It’s never good news to see a company cutting guidance, but Quest Diagnostics Inc (NYSE:DGX)’s real aim this year is to restructure its business so it can regain any market share lost to rivals like Laboratory Corp. of America Holdings (NYSE:LH) and Bio-Reference Laboratories Inc (NASDAQ:BRLI). Quest Diagnostics Inc (NYSE:DGX)’s management has acknowledged that it hasn’t grown in line with the market , and this can easily be seen by looking at its growth rates compared with those of its peers.

LH Revenue TTM Chart

LH Revenue TTM data by YCharts.

Its chief competitor, Laboratory Corp. of America Holdings (NYSE:LH), managed to grow its organic volumes at 1.4% in the last quarter and is forecasting 2% to 3% revenue growth for the full year. This is a far cry from Quest’s forecast of declining revenues.

The real question is: What is Quest doing to get back to industry growth rates?

Quest restructures and goes for growth
Earlier in the year, Quest outlined its five-point program to get back on track; I discussed this in more detail in a previous article. The good news from the company’s latest earnings results is that it appears to be executing well on the plan. The recent sale of its royalty rights to ibrutinib (an experimental cancer therapy) to Royalty Pharma for $485 million  is in line with its strategy to focus on diagnostic information services. The proceeds of the disposal will also help it to return cash to shareholders.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!